Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Mobile Application to Increase Physical Activity

28. juni 2019 opdateret af: Anna Nordström, Region Västerbotten

A Mobile Application to Increase Physical Activity, a Randomized Controlled Study

A mobile application will be tested in elderly men and women that is randomized to an application (blind-app) that registers physical activity or an application (feedback-app) where participants in addition set goals for physical activity and gets feedback from the application when these goals are achieved. Participants are randomized in permuted blocks of 10 to the blind-app or feedback-app. The primary outcome is increased physical activity. Secondary outcomes include, cardiovascular disease, diabetes, death, dementia, cancer, falls and fractures.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Detaljeret beskrivelse

In this randomized controlled study, it will be tested if a mobile application can increase physical activity and reduce the risk of later non-communicable disease.

Participants include individuals that previously have been included in a health survey (Healthy aging initiative, NCT03312439), with a low registered physical activity. Low physical is defined according to WHOs definition, i.e. at least 150 minutes of physical activity per week. Individuals will diabetes will be investigated separately.

Individuals will be excluded that cannot walk for exercise, or if they have diseases that severely affects the ability to exercise. We will also seek participants from the general population to be included with only two inclusion criteria; having a smart phone and at least 18 years of age.

Participants the meet the inclusion criteria will be randomized to an application that only registers physical activity (blind-app) or an application where the participants will set appropriate goals for physical activity and get proper feedback from the app when these goals are reached (feedback-app). Both groups will have individualized information about proper physical activity. Randomization will be made using sealed envelopes in permuted blocks of 10. Randomization will be stratified on year of birth and sex.

The primary outcome will be increased physical activity after 6 months. Secondary outcomes include cardiovascular disease, death, dementia, falls and fractures, diabetes, and improved glucose control in those that already have diabetes. Secondary outcomes also include changes in cardiovascular risk factors, such as blood pressure, blood lipids and obesity. Interaction analysis will be performed to investigate if the effects are different in men and women, based on baseline physical activity and based on age.

Based on the results from the previous health survey the individuals have participated in, a power analyses has been conducted. The participants physical activity were registered using accelerometers. The mean steps taken per week was 48000 with a standard deviation of 22000 steps. With assumption that the feedback-app will increase physical activity by at least 15%, 164 individuals would be needed in each group with an alpha level of 0.05 and a power of 80%. For secondary outcome of cardiovascular disease or death, estimates were based on incidence of these outcomes in 3617 individuals that participated in the health survey. During a mean follow up time of 928 days, 221 participants was diagnosed with cardiovascular disease or died during follow up, and 128 were diagnosed with cardiovascular disease. If assuming that the mobil-application will result in 15% lower risk of these two outcomes in those randomized to the feedback-app, 597 and 1371 individuals would be needed in each group, respectively, with the same follow up time. The effects during follow up will be monitored each year of follow up through patient registers. Follow up time is scheduled to a maximum of 2 years. We estimate that we then would need 895 and 2156 individuals in each group due to the shorter follow up time compared to in the example above.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

4000

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år til 75 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Previous participants in healthy aging initiative.

Exclusion Criteria:

  • Not able to walk or previous medical diagnoses that severely limits the possibility to exercise.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Active
Participants will be given a mobile-app where they will get feedback from the device based on their physical activity (feedback app)
The active group will be given the feedback app and the control group the blind app
Sham-komparator: Control
Participants will be given a mobile-app that does not give feedback back, but the app will register physical activity (blind app).
The active group will be given the feedback app and the control group the blind app

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Increased physical activity as measured by the mobile application in steps per day
Tidsramme: 3 years (anticipated)
Increased physical activity in steps per day during the intervention period.
3 years (anticipated)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of myocardial infarction
Tidsramme: 3 years
Diagnoses of myocardial infarction will be tracked using national registers.
3 years
Incidence of diagnosed diabetes
Tidsramme: 3 years
Diabetes diagnoses or start of treatment for diabetes will be tracked using national registers.
3 years
Incidence of diagnosed fractures
Tidsramme: 3 years
Diagnosed fractures will be tracked using national registers.
3 years
Incidence of diagnosed dementia
Tidsramme: 3 years
Diagnosed dementia or start of treatment using dementia drugs will be tracked using national registers.
3 years
Number of participants with high blood pressure
Tidsramme: 1 year (anticipated)
Systolic and diastolic blood pressure will be assessed at baseline and later using a sphygmomanometer.
1 year (anticipated)
Number of participants with high blood lipids
Tidsramme: 1 year (anticipated)
Blood lipids (cholesterol, LDL-cholesterol, and triglycerides) will be analyzed at baseline and after 6 and 12 months at the department of chemistry.
1 year (anticipated)
Number of participants with high blood glucose
Tidsramme: 1 year (anticipated)
Blood glucose will be analysed at the departement of clinical chemistry at baseline and follow up.
1 year (anticipated)
Grade of obesity
Tidsramme: 1 year (anticipated)
Obesity will be assessed using a non-elastic measurement tape at the waist
1 year (anticipated)
Body weight
Tidsramme: 1 year (anticipated)
Body weight in kilogram measured by a digital scale.
1 year (anticipated)
Incidence of stroke
Tidsramme: 3 years
Diagnoses of stroke will be tracked using national registers.
3 years
Incidence of angina pectoris
Tidsramme: 3 years
Diagnoses of angina pectoris will be tracked using national registers.
3 years
Incident mortality
Tidsramme: 3 years
Death during follow up will be tracked using national registers.
3 years
Number of participants with high glycated hemoglobin
Tidsramme: 1 year (anticipated)
Glycated hemoglobin will be measured at baseline and follow up at the Department of clinical chemistry
1 year (anticipated)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Forventet)

25. august 2019

Primær færdiggørelse (Forventet)

1. januar 2021

Studieafslutning (Forventet)

1. januar 2023

Datoer for studieregistrering

Først indsendt

14. februar 2019

Først indsendt, der opfyldte QC-kriterier

19. april 2019

Først opslået (Faktiske)

24. april 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. juli 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. juni 2019

Sidst verificeret

1. juni 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • VCC_LIFE-5

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner